

Registry General

Patent Application Advertisements

PATENT AND DESIGNS ACT 1930

February 28th, 2020

GOVERNMENT	NOTICE NO.:	2

Notice is hereby given that a person who has grounds of Opposition to the registration of any of the Patent Applications advertised herein according to the Invention claimed under the heading of "Patent Applications advertised before Registration", may within two months from the date of this publication, lodge a Notice of Opposition with the Registrar, in writing and in duplicate, accompanied by a fee of \$45.00 payable either by Cheque made payable to the Accountant General, by Cash or by Revenue Stamp obtainable at the Office of the Accountant General.

Please further note that Patent Applications filed in Bermuda for registration are shown with the Official Number accompanied by the letters BM. Patent Applications registered in the United Kingdom and filed in Bermuda are shown with the Official Number accompanied by the letters UK. Patent Applications registered in the European Union designating the United Kingdom and filed in Bermuda are shown with the Official Number accompanied by the letters EP.

PATENT APPLICATIONS ADVERTISED BEFORE REGISTRATION

BENZOXAZINONE AMIDES AS MINERALOCORTICOID RECEPTOR MODULATORS

Patent No. 630EP

On 15 March 2019, AstraZeneca AB, delivered to the Registry of Patents and Designs a signed written declaration of a certain invention, whereof the said AstraZeneca AB claims to be the Inventor or Proprietor of an invention for BENZOXAZINONE AMIDES AS MINERALOCORTICOID RECEPTOR MODULATORS, together with a specification particularly describing the nature of such invention and the manner in which the same is to be performed. The said AstraZeneca AB further requests that its name be entered in the Register of Patents as the Proprietor of this Patent.

TOPICAL FORMULATION FOR A JAK INHIBITOR

Patent No. 631EP

On 27 March 2019, Incyte Holdings Corporation, delivered to the Registry of Patents and Designs, a signed written declaration of a certain invention, whereof the said Incyte Holdings Corporation claims to be the Inventor or Proprietor of an invention for TOPICAL FORMULATION FOR A JAK INHIBITOR, together with a specification particularly describing the nature of such invention and the manner in which the same is to be performed. The said Incyte Holdings Corporation further requests that its name be entered in the Register of Patents as the Proprietor of this Patent.

Address for Service: Alexanders, Barristers & Attorneys, Belvedere Building, 69 Pitts Bay Road (Ground Floor), Pembroke HM 08, Bermuda.

COMPOSITIONS FEATURING AN ATTENUATED NEWCASTLE DISEASE VIRUS AND METHODS OF USE FOR TREATING NEOPLASIA

Patent No. 632EP

On 15 May 2019, MedImmune Limited, delivered to the Registry of Patents and Designs, a signed written declaration of a certain invention, whereof the said MedImmune Limited claims to be the Inventor or Proprietor of an invention for COMPOSITIONS FEATURING AN ATTENUATED NEWCASTLE DISEASE VIRUS AND METHODS OF USE FOR TREATING NEOPLASIA, together with a specification particularly describing the nature of such invention and the manner in which the same is to be performed. The said MedImmune Limited further requests that its name be entered in the Register of Patents as the Proprietor of this Patent.

N1-PYRAZOLOSPIROKETONE ACETYL-CoA CARBOXYLASE INHIBITORS

Patent No. 633EP

On 6 August 2019, Pfizer Inc., delivered to the Registry of Patents and Designs, a signed written declaration of a certain invention, whereof the said Pfizer Inc. claims to be the Inventor or Proprietor of an invention for N1-PYRAZOLOSPIROKETONE ACETYL-CoA CARBOXYLASE INHIBITORS, together with a specification particularly describing the nature of such invention and the manner in which the same is to be performed. The said Pfizer Inc. further requests that its name be entered in the Register of Patents as the Proprietor of this Patent.

Address for Service: Alexanders, Barristers & Attorneys, Belvedere Building, 69 Pitts Bay Road (Ground Floor), Pembroke HM 08, Bermuda.

MODULATION OF SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION 3 (STAT3) EXPRESSION

Patent No. 634EP

On **06** August **2019**, Ionis Pharmaceuticals, Inc., delivered to the Registry of Patents and Designs, a signed written declaration of a certain invention, whereof the said Ionis Pharmaceuticals, Inc. claims to be the Inventor or Proprietor of an invention for MODULATION OF SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION 3 (STAT3) EXPRESSION, together with a specification particularly describing the nature of such invention and the manner in which the same is to be performed. The said Ionis Pharmaceuticals, Inc. further requests that its name be entered in the Register of Patents as the Proprietor of this Patent.

METHODS FOR REDUCING EXACERBATION RATES OF ASTHMA USING BENRALIZUMAB

Patent No. 635EP

On 21 August 2019, AstraZeneca AB, delivered to the Registry of Patents and Designs, a signed written declaration of a certain invention, whereof the said AstraZeneca AB claims to be the Inventor or Proprietor of an invention for METHODS FOR REDUCING EXACERBATION RATES OF ASTHMA USING BENRALIZUMAB, together with a specification particularly describing the nature of such invention and the manner in which the same is to be performed. The said AstraZeneca AB further requests that its name be entered in the Register of Patents as the Proprietor of this Patent.

Address for Service: Alexanders, Barristers & Attorneys, Belvedere Building, 69 Pitts Bay Road (Ground Floor), Pembroke HM 08, Bermuda.

LANDING PAD FOR UNMANNED AERIAL VEHICLE DELIVERY

Patent No. 636EP

On 21 June 2019, Blacknight Holdings, LLC, delivered to the Registry of Patents and Designs, a signed written declaration of a certain invention, whereof the said Blacknight Holdings, LLC, claims to be the Inventor or Proprietor of an invention for LANDING PAD FOR UNMANNED AERIAL VEHICLE DELIVERY, together with a specification particularly describing the nature of such invention and the manner in which the same is to be performed. The said Blacknight Holdings, LLC, further requests that its name be entered in the Register of Patents as the Proprietor of this Patent.

Address for Service: ImPact Trademark Services LLC., Suite 206, Commerce Building, 54 Reid Street, Hamilton HM12, Bermuda.

BENZIMIDAZOLE DERIVATIVES

Patent No. 637EP

On 10 October 2019, Pfizer Inc., delivered to the Registry of Patents and Designs, a signed written declaration of a certain invention, whereof the said Pfizer Inc., claims to be the Inventor or Proprietor of an invention for BENZIMIDAZOLE DERIVATIVES, together with a specification particularly describing the nature of such invention and the manner in which the same is to be performed. The said Pfizer Inc., further requests that its name be entered in the Register of Patents as the Proprietor of this Patent.

Address for Service: Alexanders, Barristers & Attorneys, Belvedere Building, 69 Pitts Bay Road (Ground Floor), Pembroke HM 08, Bermuda.

NOVEL SELECTIVE ANDROGEN RECEPTOR MODULATORS

Patent No. 638EP

On 10 October 2019, Pfizer Inc., delivered to the Registry of Patents and Designs, a signed written declaration of a certain invention, whereof the said Pfizer Inc., claims to be the Inventor or Proprietor of an invention for NOVEL SELECTIVE ANDROGEN RECEPTOR MODULATORS together with a specification particularly describing the nature of such invention and the manner in which the same is to be performed. The said Pfizer Inc., further requests that its name be entered in the Register of Patents as the Proprietor of this Patent.

<u>Address for Service</u>: Alexanders, Barristers & Attorneys, Belvedere Building, 69 Pitts Bay Road (Ground Floor), Pembroke HM 08, Bermuda.

SUBSTITUTED TRICYCLIC COMPOUNDS AS FGFR INHIBITORS

Patent No. 639EP

On 20 November 2019, Incyte Holdings Corporation, delivered to the Registry of Patents and Designs, a signed written declaration of a certain invention, whereof the said Incyte Holdings Corporation, claims to be the Inventor or Proprietor of an invention for SUBSTITUTED TRICYCLIC COMPOUNDS AS FGFR INHIBITORS together with a specification particularly describing the nature of such invention and the manner in which the same is to be performed. The said Incyte Holdings Corporation, further requests that its name be entered in the Register of Patents as the Proprietor of this Patent.

PYRROLIDINYL UREA, PYRROLIDINYL THIOUREA AND PYRROLIDINYL GUANIDINE COMPOUNDS AS TRKA KINASE INHIBITORS

Patent No. 640EP

On 18 December 2019, Array BioPharma, Inc., delivered to the Registry of Patents and Designs, a signed written declaration of a certain invention, whereof the said Array BioPharma, Inc., claims to be the Inventor or Proprietor of an invention for PYRROLIDINYL UREA, PYRROLIDINYL THIOUREA AND PYRROLIDINYL GUANIDINE COMPOUNDS AS TRKA KINASE INHIBITORS, together with a specification particularly describing the nature of such invention and the manner in which the same is to be performed. The said Array BioPharma, Inc., further requests that its name be entered in the Register of Patents as the Proprietor of this Patent.

Address for Service: Alexanders, Barristers & Attorneys, Belvedere Building, 69 Pitts Bay Road (Ground Floor), Pembroke HM 08, Bermuda.

ANTIBODIES THAT SPECIFICALLY BIND STAPHYLOCOCCUS AUREUS ALPHA TOXIN AND METHODS OF USE

Patent No. 641EP

On 23 December 2019, MedImmune, LLC, delivered to the Registry of Patents and Designs, a signed written declaration of a certain invention, whereof the said MedImmune, LLC, claims to be the Inventor or Proprietor of an invention for ANTIBODIES THAT SPECIFICALLY BIND STAPHYLOCOCCUS AUREUS ALPHA TOXIN AND METHODS OF USE, together with a specification particularly describing the nature of such invention and the manner in which the same is to be performed. The said MedImmune, LLC, further requests that its name be entered in the Register of Patents as the Proprietor of this Patent.

5-PHENOXY-3H-PYRIMIDIN-4-ONE DERIVATIVES AND THEIR USE AS HIV REVERSE TRANSCRIPTASE INHIBITORS

Patent No. 642EP

On **07 January 2020, Merck Sharp & Dohme Corp.**, delivered to the Registry of Patents and Designs, a signed written declaration of a certain invention, whereof the said **Merck Sharp & Dohme Corp.**, claims to be the Inventor or Proprietor of an invention for **5-PHENOXY-3H-PYRIMIDIN-4-ONE DERIVATIVES AND THEIR USE AS HIV REVERSE TRANSCRIPTASE INHIBITORS**, together with a specification particularly describing the nature of such invention and the manner in which the same is to be performed. The said **Merck Sharp & Dohme Corp.**, further requests that its name be entered in the Register of Patents as the Proprietor of this Patent.

Address for Service: Alexanders, Barristers & Attorneys, Belvedere Building, 69 Pitts Bay Road (Ground Floor), Pembroke HM 08, Bermuda.

MACROCYCLIC DERIVATIVES FOR THE TREATMENT OF PROLIFERATIVE DISEASES

Patent NO. 643EP

On 24 January 2020, Pfizer Inc., delivered to the Registry of Patents and Designs, a signed written declaration of a certain invention, whereof the said Pfizer Inc., claims to be the Inventor or Proprietor of an invention for MACROCYCLIC DERIVATIVES FOR THE TREATMENT OF PROLIFERATIVE DISEASES, together with a specification particularly describing the nature of such invention and the manner in which the same is to be performed. The said Pfizer Inc., further requests that its name be entered in the Register of Patents as the Proprietor of this Patent.

BIPYRAZOLE DERIVATIVES AS JAK INHIBITORS

PATENT NO. 644EP

On **05 February 2020, Incyte Corporation**, delivered to the Registry of Patents and Designs, a signed written declaration of a certain invention, whereof the said **Incyte Corporation**, claims to be the Inventor or Proprietor of an invention for **BIPYRAZOLE DERIVATIVES AS JAK INHIBITORS**, together with a specification particularly describing the nature of such invention and the manner in which the same is to be performed. The said **Incyte Corporation**, further requests that its name be entered in the Register of Patents as the Proprietor of this Patent.

Address for Service: Alexanders, Barristers & Attorneys, Belvedere Building, 69 Pitts Bay Road (Ground Floor), Pembroke HM 08, Bermuda.

TARGETED BINDING AGENTS AGAINST B7-H1

PATENT NO. 645EP

On **05 February 2020, MedImmune Limited**, delivered to the Registry of Patents and Designs, a signed written declaration of a certain invention, whereof the said **MedImmune Limited**, claims to be the Inventor or Proprietor of an invention for **TARGETED BINDING AGENTS AGAINST B7-H1**, together with a specification particularly describing the nature of such invention and the manner in which the same is to be performed. The said **MedImmune Limited**, further requests that its name be entered in the Register of Patents as the Proprietor of this Patent.

POLYCYCLIC AMIDE DERIVATIVES AS CDK9 INHIBITORS

Patent NO. 646EP

On **05 February 2020, AstraZeneca AB**, delivered to the Registry of Patents and Designs, a signed written declaration of a certain invention, whereof the said **AstraZeneca AB**, claims to be the Inventor or Proprietor of an invention for **POLYCYCLIC AMIDE DERIVATIVES AS CDK9 INHIBITORS**, together with a specification particularly describing the nature of such invention and the manner in which the same is to be performed. The said **AstraZeneca AB**, further requests that its name be entered in the Register of Patents as the Proprietor of this Patent.